Category

News
This article was originally published on CBC ‘We still had that sense of community happening out there anyway’ Small but mighty groups of those with multiple myeloma along with their loved ones hit the streets of Halifax and beyond this weekend to raise awareness and funds. They were together, but apart, due to the ongoing pandemic. Julie...
Continue Reading
This article originally published by PharmaTimes Online The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene’s Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults. There is currently no maintenance treatment for newly diagnosed multiple myeloma in people who...
Continue Reading
This September, the International Myeloma Foundation (IMF) asks you to take part in a social media campaign to raise awareness about blood cancers, specifically multiple myeloma. So Myeloma New Zealand is taking part through placing ads online and in newspapers to raise awareness of our organisation so we can continue to help New Zealanders beat...
Continue Reading
This article was originally published by The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...
Continue Reading
This article was originally published by Cure Understanding Smoldering Multiple Myeloma Transcript: Kristie L. Kahl: Can you explain what smoldering myeloma is? Dr. Irene Ghobrial: Many patients come in to see us because they have back pain or anemia or kidney problems; however, if we know that every single patient who comes to see us with multiple...
Continue Reading
This article was originally published by AJMC Treatment Evolution in Multiple Myeloma Looking at the current state of multiple myeloma management, experts discuss interest in novel therapies and MRD assessment to guide treatment. Transcript Bruce Feinberg, DO: Hello, and welcome to this AJMC® webcast titled “Changing Patterns of Care in Multiple Myeloma.” I’m Dr Bruce Feinberg from...
Continue Reading
This article was originally published by Cancer Network The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy, according to the Janssen Pharmaceutical Companies of Johnson & Johnson, the...
Continue Reading
This article was originally published by Targeted Oncology As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, director of Myeloma Research, Sarah Cannon Research Institute, in Nashville, Tennesee, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient. Targeted Oncology™: Is this...
Continue Reading
This article was originally published by AJMC MRD Should Be More Widely Used in Clinical Care of MM, Report Argues Advances in scientists’ understanding of multiple myeloma (MM) and in the ability to assess minimal residual disease (MRD) have made the metric an important method to track the efficacy of therapy in clinical trial settings....
Continue Reading
This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested...
Continue Reading
1 10 11 12 13 14 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand